Biotron Limited reveals that its lead antiviral candidate BIT-HBV001 shows promising activity against Hepatitis Delta Virus, expanding its potential impact beyond Hepatitis B. Meanwhile, the company completes integration of Sedarex and advances regulatory plans for its anaesthetic SedRx.
- BIT-HBV001 inhibits Hepatitis Delta Virus replication by ~85%
- Co-infection with HBV and HDV linked to severe liver disease
- Sedarex acquisition fully integrated into Biotron operations
- Regulatory submissions for SedRx progressing in Europe and USA
- Investor webinar scheduled for 19 March 2026
Expanding the Antiviral Frontier
Biotron Limited (ASX:BIT) has delivered a significant update on its Hepatitis B Virus (HBV) program, revealing that its lead drug candidate, BIT-HBV001, also demonstrates potent activity against Hepatitis Delta Virus (HDV). This finding could mark a pivotal expansion in the drug’s therapeutic scope, targeting a notoriously difficult-to-treat co-infection that affects millions globally.
HDV is a satellite virus that only infects individuals already carrying HBV, and co-infection is associated with the most aggressive forms of viral hepatitis. The World Health Organization estimates that between 12 and 60 million people worldwide are infected with HDV, with co-infection often accelerating progression to cirrhosis, liver failure, or liver cancer. Biotron’s data, generated at the prestigious SCRIPPS Institute in San Diego, showed BIT-HBV001 inhibited HDV antigen production by approximately 85% in co-infected cells, a promising indicator of antiviral efficacy.
Strategic Acquisition and Regulatory Momentum
In parallel with its antiviral advances, Biotron has completed the full integration of Sedarex Limited, acquired in December 2025. Sedarex’s next-generation general anaesthetic, SedRx, is now firmly under Biotron’s operational umbrella. The company is actively engaging with European regulators, aiming to secure scientific advice from the European Medicines Agency (EMA) ahead of a July 2026 deadline. At the same time, Biotron is exploring accelerated regulatory pathways for SedRx in the United States, signalling a dual-continent strategy to bring this anaesthetic to market.
Managing Director Michelle Miller emphasised the significance of the dual antiviral and anaesthetic developments, noting that BIT-HBV001’s activity against HDV opens new avenues for addressing the most severe hepatitis infections. She highlighted the ongoing unmet need for effective HBV cures, with over 250 million people chronically infected worldwide and nearly a million deaths annually linked to HBV-related complications.
Looking Ahead
Biotron’s next steps will be closely watched by investors and industry observers alike, particularly as the company prepares for regulatory feedback on SedRx and advances its HBV program toward clinical milestones. An investor webinar scheduled for 19 March 2026 will provide an opportunity for deeper engagement and insight into these developments.
Bottom Line?
Biotron’s expanded antiviral profile and regulatory progress position it for a potentially transformative year ahead.
Questions in the middle?
- What are the timelines and next phases for clinical trials of BIT-HBV001 targeting HDV?
- How might regulatory feedback from EMA and US authorities shape SedRx’s market entry?
- What are the commercial implications of BIT-HBV001’s dual activity for Biotron’s valuation?